On January 10, 2014 the FDA announced the accelerated approval for a drug combination consisting of Trametinib (Mekinist) and Dabrafenib (Tafinlar) to treat patients with unresectable melanoma. Patients approved to receive this treatment must have the BRAF V600E mutations or BRAF V600K mutations of metastatic melanoma. Additionally, patients must have the BRAF V600E or V600K[…]
Accelerated Approval for Trametinib and Dabrafenib Combination
Chemotherapeutic / Anti-Neoplastic, Drug Research & Development API, FDA Approved 2014 Tags: 1195765-45-7Dabrafenib and TrametinibMekinistmetastatic melanomaTafinlarTrametinibunresectable melanoma Jan 29, 2014
New Trametinib and Palbociclib Combo Drug for Melanoma Being Studied
Chemotherapeutic / Anti-Neoplastic, Drug Research & Development API, FDA Breakthrough Therapy Status Tags: GlaxoSmithKlineMekinistmelanomametastatic breast cancermetastatic melanomaPfizerTrametinib Dec 17, 2013
Pfizer and GlaxoSmithKline Combat Melanoma An announcement was made by pharmaceutical giants Pfizer and GlaxoSmithKline at the end of November 2013 regarding their agreement to combine efforts in researching a novel melanoma treatment. The clinical study the two companies have commenced involves adult patients with unresectable, metastatic melanoma. This partnership will be a Phase I/II[…]
Priority Review Status Announced for Unresectable Melanoma Drugs Dabrafenib and Trametinib
Chemotherapeutic / Anti-Neoplastic, Drug Research & Development API Tags: 1195765-45-7Dabrafenib and TrametinibMekinistmetastatic melanomaTafinlarTrametinibunresectable melanoma Sep 23, 2013
On September 16, 2013 GlaxoSmithKline announced that two of their new drugs, Tafinlar {Dabrafenib} and Mekinist {Trametinib} were given priority review status from the FDA. This news is extremely exciting for researchers, practitioners and especially patients who are suffering from metastatic melanoma. As the leading cause of death from skin disease, metastatic or unresectable melanoma[…]
